Health
Biomarkers that are predictive of clinical benefit in Trop-2-expressing triple-negative breast cancer – News-Medical.Net
Oncotarget recently published “Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer” which reported that…
Reviewed by Emily Henderson, B.Sc.Nov 3 2020
Oncotarget recently published “Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer” which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.
Further, two Trop-2-transfectants of MDA-MB-231, C13, and C39, were treated in mice with SG to…
-
Noosa News23 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News22 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Business9 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General18 hours ago‘Potential’ hacker contacts Qantas over data breach